|
|
 |
|
Viewing report
|
|
|
|
Cardiovascular Drug Discoveries 2008
Espicom Business Intelligence Ltd, April 2008, Pages: 314
This market analysis provides:
Unique sales forecasts for key new and current products to 2012
A comprehensive examination of 6 major cardiovascular therapy areas
Critical analyses and competitive ratings for current and upcoming products
6 key cardiovascular therapy areas covered:
Cholesterol and Triglycerides
Hypertension
Coronary Artery Disease
Pulmonary Arterial Hypertension
Atrial Fibrillation
Thrombosis Cardiovascular disease is a global problem. In the developed world, its prevalence is linked to our increasingly unhealthy lifestyle, with risk factors including lack of exercise, overweight and obesity, and smoking. These are also linked to diabetes which increases the risk of developing heart disease.
The global desire for cheaper generic drugs has been putting increasing pressure on the research-based industry, which finds itself having to defend its patents in the courts to ward off generic competition for as long as possible. Legal battles are won and lost on both sides; either way, patents eventually expire and generic competition is inevitable.
But what of the future? Opportunities for new therapies exist in both main and niche markets - the latter being relatively uncompetitive and where there is high unmet clinical need, such as pulmonary arterial hypertension.
Among the market leaders, several will lose, or have recently lost, patent protection in major markets over the next few years. The resulting loss in revenue for the research-based industry can be dramatic.
For example, following peak sales of US$5,580 million in 2002, Merck & Co’s Zocor (simvastatin) lost its basic patent protection in Canada and a number of countries in Europe, including the UK and Germany in 2003. Sales subsequently declined in these countries as a result of generic competition.
The US patent on Zocor finally expired on 23rd June 2006, following six months paediatric extension. The FDA approved two generics with 180-days market exclusivity, resulting in a downturn in sales of Zocor to US$2.8 billion for the full year. The entry of multiple generics onto the market from December 2006, however, resulted in a dramatic fall in sales of Zocor in 2007, to US$876 million. The effect of generic simvastatin was not, however, confined to Zocor but rippled through the market, impacting sales of Pfizer’s Lipitor (atorvastatin) in the short term.
Customers who bought this item also bought
Clinical Trials in India
Booming Clinical Trials Market in India
Streamlining Clinical Trials
Industry Insight Clinical Trials in India
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
Clinical Trials in Poland 2008. Development Forecasts for 2008-2010
Clinical Trials in Poland 2008. Development Forecasts for 2008-2010
Pharmacogenomics for Clinical Use and in Drug Development
State of the Clinical Trials Industry, 2009
Therapeutic Clinical Intelligence - Psoriasis
Current Clinical Trials: Rheumatology
European E-Clinical Trials Markets
|
|
|
|
